ML-298 is a selective antagonist for the GPR6 receptor, primarily used in research settings to study its role in the central nervous system, particularly those involved in neurological disorders such as Parkinson's disease and psychiatric conditions. It acts as a valuable tool for understanding the function of GPR6 and its involvement in biological processes, including modulation of dopamine signaling pathways associated with anxiety, depression, addiction, and other disorders. Researchers utilize ML-298 in preclinical studies, including animal models, to explore its effects on behavior and neural processes, offering insights into potential therapeutic applications and drug design in neuroscience and mental health research.